血管紧张素 II 受体：抗高血压治疗的新靶点。
Angiotensin-II-receptors: new targets for antihypertensive therapy.
作者信息
Oliverio M I, Coffman T M
机构信息
Duke University Medical Center, Durham, North Carolina, USA.
出版信息
Clin Cardiol. 1997 Jan;20(1):3-6. doi: 10.1002/clc.4960200103.
Abstract
The renin-angiotensin system regulates blood pressure and sodium homeostasis through a series of coordinated substrate-enzyme interactions. These interactions result in the production of angiotensin II (AII), which exerts a number of diverse biologic effects mediated through AII cell-surface receptors. Dysregulation of this system is implicated in the pathogenesis of various forms of hypertension. Traditional therapy for hypertension has included angiotensin-converting enzyme inhibitors, which block the production of AII. However, a new class of drugs, AT1-receptor blockers, now offers a number of benefits by specifically blocking the effects of AII at its physiologically relevant receptor.
摘要
肾素-血管紧张素系统通过一系列协调的底物-酶相互作用来调节血压和钠平衡。这些相互作用导致血管紧张素II（AII）的产生，AII通过AII细胞表面受体介导多种不同的生物学效应。该系统的失调与各种形式高血压的发病机制有关。传统的高血压治疗方法包括使用血管紧张素转换酶抑制剂，这类药物可阻断AII的产生。然而，一类新型药物——AT1受体阻滞剂，通过特异性阻断AII在其生理相关受体上的作用，现在带来了许多益处。
相似文献
1
Angiotensin-II-receptors: new targets for antihypertensive therapy.血管紧张素 II 受体：抗高血压治疗的新靶点。
Clin Cardiol. 1997 Jan;20(1):3-6. doi: 10.1002/clc.4960200103.
2
Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.血管紧张素转换酶抑制剂与血管紧张素II 1型受体阻滞剂差异效应的理论基础与临床证据
Curr Opin Nephrol Hypertens. 2000 Jul;9(4):403-11. doi: 10.1097/00041552-200007000-00012.
3
Angiotensin receptors: physiology and pharmacology.
Clin Cardiol. 1995 Jun;18(6 Suppl 3):III 29-34. doi: 10.1002/clc.4960181507.
4
[The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].[血管紧张素II受体选择性阻断在心血管疾病治疗中的作用]
Clin Ter. 2001 Mar-Apr;152(2):103-6.
5
Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure.
Am Heart J. 1996 Jan;131(1):177-85. doi: 10.1016/s0002-8703(96)90067-8.
6
Pathologic consequences of increased angiotensin II activity.血管紧张素II活性增加的病理后果。
Cardiovasc Drugs Ther. 1996 Nov;10(5):511-8. doi: 10.1007/BF00050990.
7
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].[血管紧张素II AT1受体拮抗的降压优势]
Rev Esp Cardiol. 1999;52 Suppl 3:53-8.
8
Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.血管紧张素II受体阻断：心血管药物治疗的创新方法。
J Clin Pharmacol. 1993 Nov;33(11):1023-38. doi: 10.1002/j.1552-4604.1993.tb01939.x.
9
Rationale for the chemical development of angiotensin II receptor antagonists.血管紧张素II受体拮抗剂的化学研发原理。
Am J Hypertens. 1992 Dec;5(12 Pt 2):209S-220S. doi: 10.1093/ajh/5.12.209s.
10
Can large-scale trials or meta-analyses demonstrate blood pressure--independent effect of angiotensin receptor blockers?大规模试验或荟萃分析能否证明血管紧张素受体阻滞剂的血压非依赖性效应？
Hypertension. 2007 Oct;50(4):e73; author reply e74. doi: 10.1161/HYPERTENSIONAHA.107.097402. Epub 2007 Aug 27.
引用本文的文献
1
Connexin37-Dependent Mechanisms Selectively Contribute to Modulate Angiotensin II -Mediated Hypertension.连接蛋白 37 依赖性机制选择性调节血管紧张素 II 介导的高血压。
J Am Heart Assoc. 2019 Apr 16;8(8):e010823. doi: 10.1161/JAHA.118.010823.
2
Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.基于生理的瑞舒伐他汀在韩国人体内肠道BCRP介导的药物相互作用的药代动力学预测。
Korean J Physiol Pharmacol. 2018 May;22(3):321-329. doi: 10.4196/kjpp.2018.22.3.321. Epub 2018 Apr 25.
3
Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention.Wnk1激酶缺乏可降低小鼠血压：一项用于识别治疗干预潜在靶点的基因捕获筛选。
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14109-14. doi: 10.1073/pnas.2336103100. Epub 2003 Nov 10.
4
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.使用动态血压监测比较替米沙坦与缬沙坦治疗轻至中度高血压的疗效
J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4 Suppl 1):26-31. doi: 10.1111/j.1524-6175.2002.01586.x.
5
Clinical pharmacology of the angiotensin receptor antagonists.血管紧张素受体拮抗剂的临床药理学
J Clin Hypertens (Greenwich). 2001 Jan-Feb;3(1):45-9. doi: 10.1111/j.1524-6175.2001.00832.x.
本文引用的文献
1
Angiotensin II receptors and angiotensin II receptor antagonists.血管紧张素II受体与血管紧张素II受体拮抗剂
Pharmacol Rev. 1993 Jun;45(2):205-51.
2
Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition.参与抑制磷酸酪氨酸磷酸酶的新型血管紧张素II受体亚型的分子克隆
J Biol Chem. 1993 Nov 25;268(33):24543-6.
3
Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.2型血管紧张素II受体的表达克隆揭示了一类独特的七跨膜受体。
J Biol Chem. 1993 Nov 25;268(33):24539-42.
4
Differential expression of angiotensin receptor 1A and 1B in mouse.血管紧张素受体1A和1B在小鼠中的差异表达。
Am J Physiol. 1994 Aug;267(2 Pt 1):E260-7. doi: 10.1152/ajpendo.1994.267.2.E260.
5
Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study.1型血管紧张素II受体亚型的组织特异性表达。一项原位杂交研究。
Hypertension. 1994 Nov;24(5):531-7. doi: 10.1161/01.hyp.24.5.531.
6
Blood pressure effects of the angiotensin II receptor blocker, losartan.血管紧张素II受体阻滞剂氯沙坦对血压的影响。
Arch Intern Med. 1995 Feb 27;155(4):405-11.
7
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension.一项随机、安慰剂对照、双盲、平行研究，比较不同剂量氯沙坦钾与马来酸依那普利治疗原发性高血压患者的疗效。
Hypertension. 1995 Jun;25(6):1345-50. doi: 10.1161/01.hyp.25.6.1345.
8
Regulation of blood pressure by the type 1A angiotensin II receptor gene.
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3521-5. doi: 10.1073/pnas.92.8.3521.
9
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.氯沙坦钾（一种血管紧张素II受体拮抗剂）与氢氯噻嗪、阿替洛尔、缓释非洛地平和血管紧张素转换酶抑制剂相比，用于治疗系统性高血压的安全性和耐受性。
Am J Cardiol. 1995 Apr 15;75(12):793-5. doi: 10.1016/s0002-9149(99)80413-5.
10
Genetic control of blood pressure and the angiotensinogen locus.血压的遗传控制与血管紧张素原基因座
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2735-9. doi: 10.1073/pnas.92.7.2735.
Zotero 插件